CLDN18 and neoplasm: As previously observed in this tumor model, two mice treated with NTD showed varying degrees of TAC-unrelated antitumor responses which, however, was easily distinguishable from the observed CLDN18.2-TAC–specific antitumor response (Supplementary Fig. S7).